Considering that GH secretion is most commonly impaired in HPs, GH replacement therapy has been demonstrated to improve elevated levels of liver enzyme, reduce hepatic steatosis and histological changes, while also leading to a decrease in fibrotic markers (10, 11). Here, GH1 is linked to fatty liver disease.